Secoisolariciresinol diglucoside
Alternative Names: SDGLatest Information Update: 24 Oct 2021
At a glance
- Originator University of Saskatchewan
- Class Antifibrotics; Chemoprotectants; Glycosides; Lignans; Small molecules
- Mechanism of Action Antioxidants; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hypercholesterolaemia; Hypertension
Most Recent Events
- 19 Aug 2003 This compound is still in active development
- 19 Jun 2003 Preclinical trials in Hypertension in Canada (unspecified route)
- 21 May 2003 SDG has been licensed to Archer Daniel Midlands worldwide